| HLA-B* 5701 screening for hypersensitivity to abacavir S Mallal, E Phillips, G Carosi, JM Molina, C Workman, J Tomažič, ... New England Journal of Medicine 358 (6), 568-579, 2008 | 2144 | 2008 |
| ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV PIII Study, PIV Study. N Engl J Med. 22 (370(21)), 1983-92, 2014 | 993* | 2014 |
| ONCE-DAILY DOLUTEGRAVIR VERSUS DARUNAVIR PLUS RITONAVIR IN ANTIRETROVIRAL-NAIVE ADULTS WITH HIV-1 INFECTION (FLAMINGO): 48 WEEK RESULTS FROM THE RANDOMISED OPEN-LABEL PHASE 3B … INGST Bonaventura Clotet, Judith Feinberg, Jan Van Lunzen, Marie-Aude Khuong ... Lancet 383 (9936), 2222-31, 2014 | 631 | 2014 |
| The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam EJE Grosse, T Babinchak, N Dartois, G Rose, E Loh, ... Clinical infectious diseases 41 (Supplement_5), S341-S353, 2005 | 498 | 2005 |
| Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam J Breedt, J Teras, J Gardovskis, FJ Maritz, T Vaasna, DP Ross, ... Antimicrobial agents and chemotherapy 49 (11), 4658-4666, 2005 | 237 | 2005 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 216 | 2018 |
| Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients P Cahn, J Fourie, B Grinsztejn, S Hodder, JM Molina, K Ruxrungtham, ... Aids 25 (7), 929-939, 2011 | 152 | 2011 |
| Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy NH Afdhal, GM Dusheiko, EG Giannini, PJ Chen, KH Han, A Mohsin, ... Gastroenterology 146 (2), 442-452. e1, 2014 | 143 | 2014 |
| Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia C Tanaseanu, C Bergallo, O Teglia, A Jasovich, ME Oliva, G Dukart, ... Diagnostic microbiology and infectious disease 61 (3), 329-338, 2008 | 137 | 2008 |
| First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected … PENPACT-1 (PENTA 9/PACTG 390) Study Team The Lancet infectious diseases 11 (4), 273-283, 2011 | 127 | 2011 |
| Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study TM File Jr, LA Mandell, G Tillotson, K Kostov, O Georgiev Journal of Antimicrobial Chemotherapy 60 (1), 112-120, 2007 | 99 | 2007 |
| Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial JP Lalezari, GH Latiff, C Brinson, J Echevarría, S Treviño-Pérez, ... The lancet HIV 2 (10), e427-e437, 2015 | 77 | 2015 |
| Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents S Blanche, R Bologna, P Cahn, S Rugina, P Flynn, C Fortuny, P Vis, ... Aids 23 (15), 2005-2013, 2009 | 73 | 2009 |
| Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia C Tanaseanu, S Milutinovic, PI Calistru, J Strausz, M Zolubas, V Chernyak, ... BMC pulmonary medicine 9, 1-11, 2009 | 70 | 2009 |
| Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients JM Gatell, JO Morales‐Ramirez, DP Hagins, M Thompson, A Keikawus, ... Journal of the International AIDS Society 17, 19532, 2014 | 69 | 2014 |
| HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. M Grigorescu Journal of Gastrointestinal and Liver Diseases: JGLD 18 (1), 45-50, 2009 | 50 | 2009 |
| Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy MW Kline, S Rugina, M Ilie, RF Matusa, AM Schweitzer, NR Calles, ... Pediatrics 119 (5), e1116-e1120, 2007 | 42 | 2007 |
| Etravirine in treatment‐experienced, HIV‐1‐infected children and adolescents: 48‐week safety, efficacy and resistance analysis of the phase II PIANO study G Tudor‐Williams, P Cahn, K Chokephaibulkit, J Fourie, C Karatzios, ... HIV medicine 15 (9), 513-524, 2014 | 39 | 2014 |
| Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial G Fätkenheuer, C Duvivier, A Rieger, J Durant, D Rey, W Schmidt, A Hill, ... Journal of antimicrobial chemotherapy 67 (3), 685-690, 2012 | 35 | 2012 |
| PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B* 5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects S Mallal, E Phillips, G Carosi, JM Molina, C Workman, J Tomazic, ... 4th International AIDS Conference on HIV Pathogenesis, Treatment and Prevention, 2007 | 34 | 2007 |
